StonvexLoading…
StonvexStonvexStonvexCore line items from MRX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $2.02B | $1.59B | $1.24B | $711.10M |
Operating Income | $411.60M | $295.80M | $196.50M | $121.60M |
Net Income | $307.70M | $218.00M | $141.30M | $98.20M |
EPS (Diluted) | $3.86 | $2.72 | $1.82 | $1.36 |
Total Assets | $34.68B | $24.31B | $17.61B | $15.74B |
Total Liabilities | $33.41B | $23.34B | $16.84B | $15.07B |
Cash & Equivalents | $2.88B | $2.56B | $1.48B | $910.10M |
Free Cash Flow OCF − CapEx | $654.40M | $1.15B | $726.00M | $222.00M |
Shares Outstanding | Not available | Not available | Not available | Not available |